BRAF and neoplasm: During vaccination period, 16 (26.7%) patients received ICI therapy, 10 (16.7%) patients TT (BRAF inhibitors and MEK inhibitors), 1 chemotherapy, and 33 (55.0%) had no ongoing tumor therapy (NTT).